<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779519</url>
  </required_header>
  <id_info>
    <org_study_id>TTP435-201</org_study_id>
    <nct_id>NCT00779519</nct_id>
  </id_info>
  <brief_title>Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss</brief_title>
  <official_title>A Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study to Assess Safety and Tolerability of TTP435 in Obese (Class 1-2) Subjects Over 8 Weeks of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vTv Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>vTv Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple pathways including peripheral and central hormones and neurotransmitters are
      involved in the regulation of food intake and body weight. One of the most studied pathways
      involves the melanocortin receptor. Agouti-related protein (AgRP) and alpha-melanocyte
      stimulating hormone (alphaMSH)have been shown to play an integral role in food intake and
      body weight.

      It is reasonable to speculate that if there is an imbalance of alphaMSH and AgRP exist in
      obese individuals and inhibiting the activity of AgRP may be of therapeutic benefit in
      treating obesity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Adverse Events</measure>
    <time_frame>Day 1 to Day 70 (2 weeks post dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Glucose Levels</measure>
    <time_frame>Day 1 to Day 70 (2 weeks post dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Body Weight</measure>
    <time_frame>Day 1 to Day 70 (2 weeks post dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Body Mass Index</measure>
    <time_frame>Day 1 to Day 70 (2 weeks post dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight After 8 Weeks of Treatment with TTP435 or Placebo</measure>
    <time_frame>Day 1 to Day 70 (2 weeks post dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect Subject-reported Satiety</measure>
    <time_frame>Day 1 to Day 70 (2 weeks post dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Insulin Levels</measure>
    <time_frame>Day 1 to Day 70 (2 weeks post dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Free Fatty Acid Levels</measure>
    <time_frame>Day 1 to Day 70 (2 weeks post dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Leptin Levels</measure>
    <time_frame>Day 1 to Day 70 (2 weeks post dose)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TTP435</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP435</intervention_name>
    <arm_group_label>TTP435</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female volunteers, aged 18 to 65 years, inclusive.

          -  Subjects must be obese (class 1: BMI of 30.0 to 34.9 kg/m2 or class 2: BMI of 35 to
             39.9 kg/m2 in non-Asians and BMI of 27.0 - 31.9 kg/m2 or 32.0 - 36.9 kg/m2 in Asians)
             at the Screening Visit.

          -  Female subjects must be postmenopausal (with amenorrhea for at least 2 years prior to
             scheduled dosing and confirmatory FSH test in the range of 23-116 IU/L) or surgically
             sterile (with physician or insurance documentation of bilateral tubal ligation at
             least 6 months prior to Screening Visit or of a hysterectomy and/or bilateral
             oophorectomy) and agree not to undergo in vitro fertilization during the study and for
             6 months post treatment.

        Exclusion Criteria:

          -  Type 1 diabetes.

          -  Type 2 diabetes.

          -  History of myocardial infarction, stroke, including transient ischemic attack, in the
             last 2 years.

          -  Asthma or chronic obstructive pulmonary disease controlled by regular use of inhaled
             steroids.

          -  Subjects with rheumatoid arthritis, lupus, or multiple sclerosis regularly requiring
             steroids or disease-modifying anti-rheumatic agents.

          -  Subjects with psoriasis requiring oral steroids.

          -  Subjects planning to undergo gastric bypass or resection surgery, or who have had such
             a procedure in the 6 months prior to the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Wamsley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>vTv Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>26704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 5R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <disposition_first_submitted>July 15, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 20, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 22, 2010</disposition_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jane Shen, Pharm.D.</name_title>
    <organization>TransTech Pharma</organization>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Class 1</keyword>
  <keyword>Class 2</keyword>
  <keyword>Weight Loss</keyword>
  <keyword>AgRP</keyword>
  <keyword>TTP435</keyword>
  <keyword>alphaMSH</keyword>
  <keyword>Agouti-Related Protein</keyword>
  <keyword>alpha-melanocyte stimulating hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

